• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimizing the pharmacokinetics of sonidegib in small bowel syndrome and advanced basal cell carcinoma: Our solution.

作者信息

Grubbs Hailey, Cortes Marianne, Strasswimmer John

机构信息

Dermatology Department, Broward Health Medical Center, Ft Lauderdale, Florida.

Nova Southeastern University Kiran C Patel College of Osteopathic Medicine, Davie, Florida.

出版信息

JAAD Case Rep. 2023 Jun 20;38:152-154. doi: 10.1016/j.jdcr.2023.06.016. eCollection 2023 Aug.

DOI:10.1016/j.jdcr.2023.06.016
PMID:37521196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10374436/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/286a/10374436/99cba9d918b4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/286a/10374436/9810ad31e6be/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/286a/10374436/0288b8c7befa/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/286a/10374436/99cba9d918b4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/286a/10374436/9810ad31e6be/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/286a/10374436/0288b8c7befa/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/286a/10374436/99cba9d918b4/gr3.jpg

相似文献

1
Optimizing the pharmacokinetics of sonidegib in small bowel syndrome and advanced basal cell carcinoma: Our solution.优化索纳替尼在小肠综合征和晚期基底细胞癌中的药代动力学：我们的解决方案。
JAAD Case Rep. 2023 Jun 20;38:152-154. doi: 10.1016/j.jdcr.2023.06.016. eCollection 2023 Aug.
2
A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.《Hedgehog 抑制剂索立德吉和维莫德吉治疗晚期基底细胞癌的研究综述》。
J Drugs Dermatol. 2021 Feb 1;20(2):156-165. doi: 10.36849/JDD.5657.
3
Benefit-risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma.索尼德吉和维莫德吉治疗局部晚期基底细胞癌的获益-风险评估
Drugs Context. 2022 Jul 7;11. doi: 10.7573/dic.2022-1-2. eCollection 2022.
4
Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.维莫德吉和索尼德吉治疗局部晚期和转移性基底细胞癌： hedgehog 通路抑制剂的最新进展。
Actas Dermosifiliogr. 2022 May;113(5):443-450. doi: 10.1016/j.ad.2022.01.005. Epub 2022 Jan 31.
5
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.BOLT 研究：隆地替尼治疗基底细胞癌的 12 个月分析：一项评价晚期基底细胞癌患者接受 sonidegib 治疗的 II 期、随机、双盲研究。
J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5. doi: 10.1016/j.jaad.2016.02.1226. Epub 2016 Apr 7.
6
Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.索尼德吉用于治疗晚期基底细胞癌。
Front Oncol. 2020 Oct 30;10:582866. doi: 10.3389/fonc.2020.582866. eCollection 2020.
7
Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis.使用索尼德吉或维莫德吉治疗的晚期基底细胞癌患者的关键临床不良事件：一项事后分析
Dermatol Ther (Heidelb). 2021 Oct;11(5):1839-1849. doi: 10.1007/s13555-021-00588-8. Epub 2021 Sep 6.
8
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.索纳替尼和维莫德吉治疗局部晚期基底细胞癌患者：联合专家意见
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1944-1956. doi: 10.1111/jdv.16230. Epub 2020 Mar 4.
9
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.索立德吉治疗晚期基底细胞癌的长期疗效和安全性：II 期随机、双盲 BOLT 研究的 42 个月分析。
Br J Dermatol. 2020 Jun;182(6):1369-1378. doi: 10.1111/bjd.18552. Epub 2019 Dec 8.
10
Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.Sonic Hedgehog 通路抑制在晚期基底细胞癌治疗中的应用。
Curr Treat Options Oncol. 2019 Nov 26;20(11):84. doi: 10.1007/s11864-019-0683-9.

引用本文的文献

1
Twelve-year continuous therapy with vismodegib for advanced basal cell carcinoma: Tolerability and partial reversibility of adverse events.维莫德吉用于晚期基底细胞癌的12年持续治疗：不良事件的耐受性和部分可逆性
JAAD Case Rep. 2024 May 14;64:7-9. doi: 10.1016/j.jdcr.2024.05.004. eCollection 2025 Oct.

本文引用的文献

1
Patidegib in Dermatology: A Current Review.派蒂德吉布在皮肤科的应用：综述
Int J Mol Sci. 2021 Oct 3;22(19):10725. doi: 10.3390/ijms221910725.
2
High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.高危复发性基底细胞癌：聚焦 Hedgehog 通路抑制剂及文献复习。
Chemotherapy. 2020;65(1-2):2-10. doi: 10.1159/000509156. Epub 2020 Aug 10.
3
Arsenic Trioxide, Itraconazole, All-Trans Retinoic Acid and Nicotinamide: A Proof of Concept for Combined Treatments with Hedgehog Inhibitors in Advanced Basal Cell Carcinoma.
三氧化二砷、伊曲康唑、全反式维甲酸和烟酰胺：晚期基底细胞癌中与刺猬信号通路抑制剂联合治疗的概念验证
Biomedicines. 2020 Jun 11;8(6):156. doi: 10.3390/biomedicines8060156.
4
To Take or Not to Take With Meals? Unraveling Issues Related to Food Effects Labeling for Oral Antineoplastic Drugs.是否随餐服用？解析口服抗肿瘤药物食物影响标签相关问题
Clin Pharmacol Drug Dev. 2018 Jun;7(5):455-464. doi: 10.1002/cpdd.416. Epub 2017 Dec 2.
5
Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas.索尼德吉：晚期基底细胞癌的作用机制、药理学及临床应用
Onco Targets Ther. 2017 Mar 16;10:1645-1653. doi: 10.2147/OTT.S130910. eCollection 2017.
6
Spontaneous resolution of advanced basal cell carcinoma after short-pulse treatment with hedgehog pathway inhibitor.经刺猬信号通路抑制剂短脉冲治疗后晚期基底细胞癌的自发消退
JAAD Case Rep. 2016 Aug 30;2(4):360-1. doi: 10.1016/j.jdcr.2016.06.010. eCollection 2016 Jul.
7
Four-year experience with vismodegib hedgehog inhibitor therapy.维莫德吉（vismodegib）刺猬因子抑制剂治疗的四年经验
J Am Acad Dermatol. 2016 Jun;74(6):1264-5. doi: 10.1016/j.jaad.2015.12.035.
8
Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.Hedgehog 通路抑制剂治疗局部晚期和转移性基底细胞癌：干预性研究的系统评价和汇总分析。
JAMA Dermatol. 2016 Jul 1;152(7):816-24. doi: 10.1001/jamadermatol.2016.0780.